inogatran has been researched along with Disease Models, Animal in 6 studies
*Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases. [MeSH]
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (50.00) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Avdeef, A; Tam, KY | 1 |
| Frebelius, S; Swedenborg, J; Wahlgren, CM | 1 |
| Grip, L; Mattsson, C; Rydén, L; Sjöquist, PO; Uriuda, Y; Wang, QD | 1 |
| Börjesson, I; Elg, M; Gustafsson, D; Lenfors, S; Teger-Nilsson, AC | 1 |
| Carlsson, S; Eriksson, BI; Halvarsson, M; Mattsson, C; Risberg, B | 1 |
| Bousley, RF; Chi, L; Gallagher, KP; Janiczek, N; Juneau, PL; Mertz, TE; Peng, YW; Rogers, KL; Saganek, L; Uprichard, AC | 1 |
6 other study(ies) available for inogatran and Disease Models, Animal
| Article | Year |
|---|---|
How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
Topics: Animals; Disease Models, Animal; Dogs; Humans; Jejunal Diseases; Kidney Diseases; Models, Biological; Permeability; Porosity; Regression Analysis | 2010 |
Inhibition of neointimal hyperplasia by a specific thrombin inhibitor.
Topics: Animals; Antithrombins; Biomarkers; Disease Models, Animal; Glycine; Hyperplasia; Male; Models, Cardiovascular; Piperidines; Rats; Rats, Sprague-Dawley; Tunica Intima | 2004 |
Antithrombotic activity of inogatran, a new low-molecular-weight inhibitor of thrombin, in a closed-chest porcine model of coronary artery thrombosis.
Topics: Animals; Aspirin; Coronary Thrombosis; Disease Models, Animal; Female; Glycine; Heparin; Male; Piperidines; Swine; Thrombin | 1996 |
Effects of inogatran, a new low-molecular-weight thrombin inhibitor, in rat models of venous and arterial thrombosis, thrombolysis and bleeding time.
Topics: Animals; Antithrombins; Arginine; Aspirin; Bleeding Time; Disease Models, Animal; Fibrinolytic Agents; Glycine; Heparin; Male; Molecular Weight; Pipecolic Acids; Piperidines; Platelet Aggregation Inhibitors; Rats; Rats, Sprague-Dawley; Sulfonamides; Thrombolytic Therapy; Thrombophlebitis; Thrombosis | 1996 |
Antithrombotic effect of two low molecular weight thrombin inhibitors and a low-molecular weight heparin in a caval vein thrombosis model in the rat.
Topics: Animals; Azetidines; Benzylamines; Dalteparin; Disease Models, Animal; Fibrinolytic Agents; Glycine; Heparin, Low-Molecular-Weight; Infusions, Intravenous; Injections, Intravenous; Male; Piperidines; Rats; Rats, Wistar; Thrombin; Thrombophlebitis; Vena Cava, Inferior | 1997 |
Antithrombotic effect of LB-30057 (CI-1028), a new synthetic thrombin inhibitor, in a rabbit model of thrombosis: comparison with inogatran.
Topics: Animals; Benzamides; Bleeding Time; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Fibrinolytic Agents; Glycine; Hemostasis; Implants, Experimental; Injections; Piperidines; Rabbits; Regional Blood Flow; Thrombin; Thrombosis; Vena Cava, Superior | 2001 |